呂星，主任醫師，中山大學腫瘤防治中心鼻咽科師生第二黨支部書記，中山大學腫瘤防治中心人工智慧實驗室特聘臨床專家，院職代會常設委員會委員。
基本介紹
- 中文名：呂星
- 國籍：中國
- 臨床職稱：主任醫師
- 執業地點：中山大學腫瘤防治中心
獲獎情況,學術任職,擅長領域,科研成果,發表論文,
獲獎情況
2018年中國臨床腫瘤學會（CSCO）優秀論文二等獎
2020年度人民好醫生金山茶花•傑出貢獻獎
中山大學腫瘤防治中心住院醫師規範化培訓優秀帶教教師
學術任職
中國醫師協會放療專業委員會 青年委員
中國抗癌協會腫瘤微環境專業委員會 青年委員
廣東省抗癌協會放療專業委員會青委會 副主任委員
廣東省抗癌協會鼻咽癌專業委員會 青年委員
廣東省醫療行業協會耳鼻喉頭頸外科管理委員會 常委委員
廣東省器官醫學與技術學會腫瘤放療專業委員會 副主任委員
廣州市荔灣區醫療保健專家 顧問
擅長領域
鼻咽癌的個體化綜合治療及人工智慧輔助診斷、治療鼻咽癌。
科研成果
1.基於時序性磁共振圖像的局部晚期鼻咽癌個體化化療方案與實時預後預測的人工智慧模型，國家自然科學基金面上項目，55萬，執行年限：2022-2025，負責人。
2.基於人工智慧和跨組學大數據的鼻咽癌診治精準化研究，廣東省自然科學基金傑出青年項目，100萬，執行年限：2023-2026，負責人。
3.CD36促進鼻咽癌形成循環腫瘤細胞並啟動鼻咽癌轉移的分子機制及潛在治療靶點的研究，廣東省自然科學基金面上項目，10萬 ，執行年限： 2021-2023，負責人。
4.基於光聲成像的鼻咽癌雷射免疫精準診療技術研究，廣東省精準醫學重大科技專項項目子課題，300萬，執行年限：2019-2021，第二負責人。
5.Latexin調節腫瘤微環境促進鼻咽癌侵襲和轉移分子機制的研究，廣東省自然科學基金國際合作項目,50萬，執行年限：2016-2017，負責人
發表論文
1.Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, Qian CN, Cao KJ, Mo HY, Li XM, Li ZH, Han F, He YX, Liu YM, Wu SX, Bai YR, Ke LR, Qiu WZ, Liang H, Liu GY, Miao JJ, Li WZ, Lv SH, Chen X, Zhao C, Xiang YQ, Guo X. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):716-726. doi: 10.1016/S1470-2045(21)00075-9. Epub 2021 Apr 12. PMID: 33857411.
2.Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, Ye YF, Yang W, Zhang HX, Yuan TZ, Wang DS, Lu N, Ke LR, Tang WB, Tong LH, Chen ZJ, Liu T, Cao KJ, Mo HY, Guo L, Zhao C, Chen MY, Chen QY, Huang PY, Sun R, Qiu F, Luo DH, Wang L, Hua YJ, Tang LQ, Qian CN, Mai HQ, Guo X, Xiang YQ, Xia WX. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):706-714. doi: 10.1001/jamaoncol.2022.0122. PMID: 35323856; PMCID: PMC8949760.
3.Qiang M, Li C, Sun Y, Sun Y, Ke L, Xie C, Zhang T, Zou Y, Qiu W, Gao M, Li Y, Li X, Zhan Z, Liu K, Chen X, Liang C, Chen Q, Mai H, Xie G, Guo X, Lv X. A Prognostic Predictive System Based on Deep Learning for Locoregionally Advanced Nasopharyngeal Carcinoma. J Natl Cancer Inst. 2021 May 4;113(5):606-615. doi: 10.1093/jnci/djaa149. PMID: 32970812; PMCID: PMC8096375.
4.Li C, Jing B, Ke L, Li B, Xia W, He C, Qian C, Zhao C, Mai H, Chen M, Cao K, Mo H, Guo L, Chen Q, Tang L, Qiu W, Yu Y, Liang H, Huang X, Liu G, Li W, Wang L, Sun R, Zou X, Guo S, Huang P, Luo D, Qiu F, Wu Y, Hua Y, Liu K, Lv S, Miao J, Xiang Y, Sun Y, Guo X, Lv X. Development and validation of an endoscopic images-based deep learning model for detection with nasopharyngeal malignancies. Cancer Commun (Lond). 2018 Sep 25;38(1):59. doi: 10.1186/s40880-018-0325-9. PMID: 30253801; PMCID: PMC6156962.
5.Xia WX, Lv X, Liang H, Liu GY, Sun R, Zeng Q, Li SW, Mo HY, Han F, Luo DH, Liu Q, Shi MY, Ye YF, Yang J, Ke LR, Qiang MY, Qiu WZ, Yu YH, Liu KY, Huang XJ, Li WZ, Lv SH, Cai ZC, Miao JJ, Guo L, Chen MY, Cao KJ, Wang L, Zhao C, Huang PY, Chen QY, Hua YJ, Tang LQ, Qian CN, Mai HQ, Guo X, Xiang YQ. A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer. Clin Cancer Res. 2021 Aug 1;27(15):4186-4194. doi: 10.1158/1078-0432.CCR-20-4532. Epub 2021 Jun 3. PMID: 34083231; PMCID: PMC8974421.
6.Qiu WZ, Zhang HB, Xia WX, Ke LR, Yang J, Yu YH, Liang H, Huang XJ, Liu GY, Li WZ, Xiang YQ, Kang TB, Guo X, Lv X. The CXCL5/CXCR2 axis contributes to the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells by activating ERK/GSK-3β/snail signalling. J Exp Clin Cancer Res. 2018 Apr 17;37(1):85. doi: 10.1186/s13046-018-0722-6. PMID: 29665837; PMCID: PMC5905166.
7.Liu GY, Lv X, Wu YS, Mao MJ, Ye YF, Yu YH, Liang H, Yang J, Ke LR, Qiu WZ, Huang XJ, Li WZ, Guo X, Xiang YQ, Xia WX. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Cancer Commun (Lond). 2018 May 10;38(1):21. doi: 10.1186/s40880-018-0283-2. PMID: 29764487; PMCID: PMC5993041.
8.Liu K, Xia W, Qiang M, Chen X, Liu J, Guo X, Lv X. Deep learning pathological microscopic features in endemic nasopharyngeal cancer: Prognostic value and protentional role for individual induction chemotherapy. Cancer Med. 2020 Feb;9(4):1298-1306. doi: 10.1002/cam4.2802. Epub 2019 Dec 20. PMID: 31860791; PMCID: PMC7013063.
9.Cao X, Chen X, Lin ZC, Liang CX, Huang YY, Cai ZC, Li JP, Gao MY, Mai HQ, Li CF, Guo X, Lyu X. Add-on individualizing prediction of nasopharyngeal carcinoma using deep-learning based on MRI: A multicentre, validation study. iScience. 2022 Aug 3;25(9):104841. doi: 10.1016/j.isci.2022.104841. PMID: 36034225; PMCID: PMC9399485.
10.Chen X, Li Y, Li X, Cao X, Xiang Y, Xia W, Li J, Gao M, Sun Y, Liu K, Qiang M, Liang C, Miao J, Cai Z, Guo X, Li C, Xie G, Lv X. An interpretable machine learning prognostic system for locoregionally advanced nasopharyngeal carcinoma based on tumor burden features. Oral Oncol. 2021 Jul;118:105335. doi: 10.1016/j.oraloncology.2021.105335. Epub 2021 May 21. PMID: 34023742.
11.Chen X, Cao X, Jing B, Xia W, Ke L, Xiang Y, Liu K, Qiang M, Liang C, Li J, Gao M, Li W, Miao J, Liu G, Cai Z, Lv S, Guo X, Li C, Lv X. Prognostic and Treatment Guiding Significance of MRI-Based Tumor Burden Features and Nodal Necrosis in Nasopharyngeal Carcinoma. Front Oncol. 2020 Sep 11;10:537318. doi: 10.3389/fonc.2020.537318. PMID: 33042831; PMCID: PMC7518313.
12.Cai Z, Chen D, Qiu W, Liang C, Huang Y, Zhou J, Zhan Z, Xiang Y, Guo X, Lv X. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis. J Cancer Res Clin Oncol. 2022 Oct 27. doi: 10.1007/s00432-022-04355-w. Epub ahead of print. PMID: 36289067.
13.Liu GY, Li WZ, Wang DS, Liang H, Lv X, Ye YF, Zhao C, Ke LR, Lv SH, Lu N, Bei WX, Cai ZC, Chen X, Liang CX, Guo X, Xia WX, Xiang YQ. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Apr 1;8(4):553-561. doi: 10.1001/jamaoncol.2021.7366. PMID: 35175316; PMCID: PMC8855317.
14.Liu YP, Lv X, Zou X, Hua YJ, You R, Yang Q, Xia L, Guo SY, Hu W, Zhang MX, Chen SY, Lin M, Xie YL, Liu LZ, Sun R, Huang PY, Fan W, Guo X, Hong MH, Chen MY. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma. Cancer Commun (Lond). 2019 Nov 15;39(1):75. doi: 10.1186/s40880-019-0415-3. PMID: 31730020; PMCID: PMC6858734.
15.Liang H, Xiang YQ, Lv X, Xie CQ, Cao SM, Wang L, Qian CN, Yang J, Ye YF, Gan F, Ke LR, Yu YH, Liu GY, Qiu WZ, Huang XJ, Wen CH, You N, Wang XQ, Guo X, Xia WX. Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: A large institution-based cohort study from an endemic area. Eur J Cancer. 2017 Mar;73:48-60. doi: 10.1016/j.ejca.2016.12.009. Epub 2017 Feb 3. PMID: 28161498.
16.Deng Y, Li C, Lv X, Xia W, Shen L, Jing B, Li B, Guo X, Sun Y, Xie C, Ke L. The contrast-enhanced MRI can be substituted by unenhanced MRI in identifying and automatically segmenting primary nasopharyngeal carcinoma with the aid of deep learning models: An exploratory study in large-scale population of endemic area. Comput Methods Programs Biomed. 2022 Apr;217:106702. doi: 10.1016/j.cmpb.2022.106702. Epub 2022 Feb 16. PMID: 35228147.
17.Liang H, Lv X, Wang L, Wu YS, Sun R, Ye YF, Ke LR, Yang Q, Yu YH, Qiu WZ, Liu GY, Huang XJ, Li WZ, Lv SH, Guo X, Xiang YQ, Xia WX. The plasma Epstein-Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area. Ther Adv Med Oncol. 2018 Jul 20;10:1758835918782331. doi: 10.1177/1758835918782331. PMID: 30046357; PMCID: PMC6055246.
18.Jing B, Deng Y, Zhang T, Hou D, Li B, Qiang M, Liu K, Ke L, Li T, Sun Y, Lv X, Li C. Deep learning for risk prediction in patients with nasopharyngeal carcinoma using multi-parametric MRIs. Comput Methods Programs Biomed. 2020 Dec;197:105684. doi: 10.1016/j.cmpb.2020.105684. Epub 2020 Aug 2. PMID: 32781421.
19.Xia WX, Liang H, Lv X, Wang L, Qian CN, Ye YF, Ke LR, Qiu WZ, Yu YH, Huang XJ, Liu GY, Zhao C, Xiang YQ, Guo X. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis. Oral Oncol. 2017 Apr;67:167-174. doi: 10.1016/j.oraloncology.2017.02.026. Epub 2017 Mar 2. PMID: 28351572.
20.Ke LR, Xia WX, Qiu WZ, Huang XJ, Yu YH, Liang H, Liu GY, Xiang YQ, Guo X, Lv X. A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma. Oral Oncol. 2017 Jul;70:7-13. doi: 10.1016/j.oraloncology.2017.04.018. Epub 2017 May 9. PMID: 28622892.
21.Ke L, Deng Y, Xia W, Qiang M, Chen X, Liu K, Jing B, He C, Xie C, Guo X, Lv X, Li C. Development of a self-constrained 3D DenseNet model in automatic detection and segmentation of nasopharyngeal carcinoma using magnetic resonance images. Oral Oncol. 2020 Nov;110:104862. doi: 10.1016/j.oraloncology.2020.104862. Epub 2020 Jun 29. PMID: 32615440.
22.Liu K, Lin S, Ke L, Xia W, Zhang C, Li J, Gao M, Qiang M, Chen X, Liu J, Xie C, Guo X, Lv X. Prognostic value and the potential role of treatment options for cervical lymph node necrosis in nasopharyngeal carcinoma. Oral Oncol. 2020 Jun 27;109:104864. doi: 10.1016/j.oraloncology.2020.104864. Epub ahead of print. PMID: 32604061.
23.He C, Huang X, Su X, Tang T, Zhang X, Ma J, Guo X, Lv X. The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma. Cancer Biol Ther. 2017 Nov 2;18(11):888-894. doi: 10.1080/15384047.2017.1281493. Epub 2017 Jan 25. PMID: 28121221; PMCID: PMC5710676.
24.Ke LR, Xia WX, Qiu WZ, Huang XJ, Yang J, Yu YH, Liang H, Liu GY, Ye YF, Xiang YQ, Guo X, Lv X. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. BMC Cancer. 2017 Feb 15;17(1):134. doi: 10.1186/s12885-017-3080-4. PMID: 28202000; PMCID: PMC5311839.
25.Yu Y, Ke L, Xia WX, Xiang Y, Lv X, Bu J. Elevated Levels of TNF-α and Decreased Levels of CD68-Positive Macrophages in Primary Tumor Tissues Are Unfavorable for the Survival of Patients With Nasopharyngeal Carcinoma. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819874807. doi: 10.1177/1533033819874807. PMID: 31522611; PMCID: PMC6747870.
26.Qiu WZ, Ke LR, Xia WX, Yang J, Yu YH, Liang H, Huang XJ, Liu GY, Li WZ, Xiang YQ, Guo X, Lv X. A retrospective study of 606 cases of nasopharyngeal carcinoma with or without oropharyngeal candidiasis during radiotherapy. PLoS One. 2017 Aug 10;12(8):e0182963. doi: 10.1371/journal.pone.0182963. PMID: 28797119; PMCID: PMC5552301.
